Moreover, preclinical studies indicate that TAAR1 can modulate the activity of several neurotransmitter systems (such as dopamine, serotonin, and glutamate), which dysregulation is believed to be involved in the pathogenesis of schizophrenia. Here, TAAR1 is linked to schizophrenia.